Originally published by our sister publication Gastroenterology & Endoscopy News
By Chase Doyle
Laura Targownik, MD, MSHS
DENVER—Dual-targeted therapy has emerged as a promising approach for inflammatory bowel disease when the limits of monotherapies may have been reached, but more evidence on the safety and efficacy of this approach is needed, according to presentations at the 2023 annual Crohn’s & Colitis Congress.
There are several settings in which the use of dual-targeted